Published in Blood on October 21, 2008
Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol (2010) 7.75
From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer (2009) 4.15
MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One (2009) 3.66
microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood (2010) 2.25
MicroRNA-34a induces endothelial progenitor cell senescence and impedes its angiogenesis via suppressing silent information regulator 1. Am J Physiol Endocrinol Metab (2010) 1.73
Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood (2009) 1.70
MicroRNA-34a perturbs B lymphocyte development by repressing the forkhead box transcription factor Foxp1. Immunity (2010) 1.70
C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations. Blood (2010) 1.28
miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia. Blood (2009) 1.25
Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes. Blood (2009) 1.21
MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia. Mol Cancer (2010) 1.18
Microprocessor of microRNAs: regulation and potential for therapeutic intervention. Mol Cancer (2010) 1.11
miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Neuro Oncol (2010) 1.10
Regulatory mechanisms and clinical perspectives of miRNA in tumor radiosensitivity. Carcinogenesis (2012) 1.10
MicroRNAs in B cell development and malignancy. J Hematol Oncol (2012) 1.08
Transcriptional activation of microRNA-34a by NF-kappa B in human esophageal cancer cells. BMC Mol Biol (2012) 1.08
MicroRNAs in B-cell lymphomas: how a complex biology gets more complex. Leukemia (2014) 1.08
Rhamnetin and cirsiliol induce radiosensitization and inhibition of epithelial-mesenchymal transition (EMT) by miR-34a-mediated suppression of Notch-1 expression in non-small cell lung cancer cell lines. J Biol Chem (2013) 1.01
p53-dependent non-coding RNA networks in chronic lymphocytic leukemia. Leukemia (2015) 1.01
Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia. Mol Cancer (2010) 1.00
Targeted expression of miR-34a using the T-VISA system suppresses breast cancer cell growth and invasion. Mol Ther (2012) 1.00
Integrating sequence, expression and interaction data to determine condition-specific miRNA regulation. Bioinformatics (2013) 0.97
Involvement of microRNAs in lung cancer biology and therapy. Transl Res (2011) 0.96
Ectopic expression of miR-34a enhances radiosensitivity of non-small cell lung cancer cells, partly by suppressing the LyGDI signaling pathway. J Radiat Res (2013) 0.95
MiR-181b: new perspective to evaluate disease progression in chronic lymphocytic leukemia. Oncotarget (2012) 0.95
Inactivation of miR-34a by aberrant CpG methylation in Kazakh patients with esophageal carcinoma. J Exp Clin Cancer Res (2014) 0.94
The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: implications for therapy in p53-defective CLL patients. Leukemia (2013) 0.94
Principles of microRNA involvement in human cancers. Chin J Cancer (2011) 0.94
MicroRNAs in human embryonic and cancer stem cells. Yonsei Med J (2010) 0.93
Zerumbone, a Southeast Asian Ginger Sesquiterpene, Induced Apoptosis of Pancreatic Carcinoma Cells through p53 Signaling Pathway. Evid Based Complement Alternat Med (2012) 0.93
Cisplatin-induced epigenetic activation of miR-34a sensitizes bladder cancer cells to chemotherapy. Mol Cancer (2014) 0.91
The new concepts on overcoming drug resistance in lung cancer. Drug Des Devel Ther (2014) 0.91
Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks. Cancer Biol Med (2013) 0.89
Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML. Blood (2014) 0.87
IL-4 Up-Regulates MiR-21 and the MiRNAs Hosted in the CLCN5 Gene in Chronic Lymphocytic Leukemia. PLoS One (2015) 0.87
Functional assessment of p53 in chronic lymphocytic leukemia. Blood Cancer J (2011) 0.85
microRNA expression and biogenesis in cellular response to ionizing radiation. DNA Cell Biol (2014) 0.84
Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups. Cancer Med (2014) 0.84
Noncoding RNA and colorectal cancer: its epigenetic role. J Hum Genet (2016) 0.84
MicroRNA-regulated pathways in hematological malignancies: how to avoid cells playing out of tune. Int J Mol Sci (2013) 0.82
Modulation of cancer traits by tumor suppressor microRNAs. Int J Mol Sci (2013) 0.82
Critical signal transduction pathways in CLL. Adv Exp Med Biol (2013) 0.81
Refinement of 1p36 alterations not involving PRDM16 in myeloid and lymphoid malignancies. PLoS One (2011) 0.81
Role of microRNAs on therapy resistance in Non-Hodgkin's lymphoma. Int J Clin Exp Med (2014) 0.81
MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies. ISRN Hematol (2013) 0.80
Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia. Leukemia (2016) 0.80
miR deregulation in CLL. Adv Exp Med Biol (2013) 0.79
Identification of novel sequence variations in microRNAs in chronic lymphocytic leukemia. Carcinogenesis (2013) 0.79
Role of microRNAs in chemoresistance. Ann Transl Med (2015) 0.79
Analysis of the miR-34a locus in 62 patients with familial cutaneous melanoma negative for CDKN2A/CDK4 screening. Fam Cancer (2012) 0.79
miRNA-mediated deregulation in leukemia. Front Genet (2012) 0.78
The predictive effect of overexpressed miR-34a on good survival of cancer patients: a systematic review and meta-analysis. Onco Targets Ther (2015) 0.78
MicroRNA-34a regulates liver regeneration and the development of liver cancer in rats by targeting Notch signaling pathway. Oncotarget (2017) 0.77
microRNA-34b/c on chromosome 11q23 is aberrantly methylated in chronic lymphocytic leukemia. Epigenetics (2014) 0.77
Mir-34a mimics are potential therapeutic agents for p53-mutated and chemo-resistant brain tumour cells. PLoS One (2014) 0.77
MiR-sensing chemotherapy resistance in CLL. Blood (2009) 0.77
Nutlin-3 differentially modulates miRNA34a and miRNA181 versus miR26a and miR155 in p53 proficient and p53 deficient B chronic lymphocytic leukemia (B-CLL) samples. Invest New Drugs (2011) 0.77
A p53 axis regulates B cell receptor-triggered, innate immune system-driven B cell clonal expansion. J Immunol (2012) 0.77
The role of TP53 network in the pathogenesis of chronic lymphocytic leukemia. Int J Clin Exp Pathol (2013) 0.77
Novel mechanisms of regulation of miRNAs in CLL. Trends Cancer (2016) 0.77
Signaling of miRNAs-FOXM1 in cancer and potential targeted therapy. Curr Drug Targets (2013) 0.76
Role of microRNA in chronic lymphocytic leukemia onset and progression. J Hematol Oncol (2015) 0.76
The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells. Oncotarget (2015) 0.76
Protein expression analysis of chronic lymphocytic leukemia defines the effect of genetic aberrations and uncovers a correlation of CDK4, P27 and P53 with hierarchical risk. Haematologica (2010) 0.75
Targeting the TAM Receptors in Leukemia. Cancers (Basel) (2016) 0.75
Modeling miRNA-mRNA interactions that cause phenotypic abnormality in breast cancer patients. PLoS One (2017) 0.75
Alternative mechanisms of miR-34a regulation in cancer. Cell Death Dis (2017) 0.75
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med (2008) 13.02
Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med (2004) 9.81
Acute myeloid leukaemia. Lancet (2006) 7.74
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med (2014) 6.80
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med (2013) 6.70
Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell (2012) 6.07
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med (2013) 5.72
CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol (2004) 5.01
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med (2014) 4.98
High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med (2009) 4.90
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol (2010) 4.79
IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol (2010) 4.72
Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. J Clin Oncol (2006) 4.49
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood (2008) 4.26
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood (2012) 4.17
From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer (2009) 4.15
Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol (2011) 3.34
TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood (2011) 3.32
TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol (2010) 3.26
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell (2007) 3.23
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol (2011) 3.21
First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood (2009) 3.21
V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood (2002) 3.17
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood (2005) 3.14
Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. Cancer Cell (2012) 3.10
MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood (2008) 3.03
Human chromosome 7: DNA sequence and biology. Science (2003) 3.02
Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol (2012) 3.00
Acute Myeloid Leukemia. N Engl J Med (2015) 2.85
Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov (2013) 2.74
Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci U S A (2004) 2.46
Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol (2012) 2.35
Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol (2008) 2.32
Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. J Clin Oncol (2009) 2.23
Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol (2006) 2.15
CD20 deficiency in humans results in impaired T cell-independent antibody responses. J Clin Invest (2009) 2.15
RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol (2011) 2.11
Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood (2010) 2.04
Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia. Blood (2007) 2.02
Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol (2009) 2.00
Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica (2007) 1.99
CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood (2003) 1.99
Apoptosis threshold set by Noxa and Mcl-1 after T cell activation regulates competitive selection of high-affinity clones. Immunity (2010) 1.98
Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions. Nat Immunol (2002) 1.97
The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood (2010) 1.96
Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. J Clin Oncol (2004) 1.92
V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood (2005) 1.92
Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol (2002) 1.91
Characterization of structurally defined epitopes recognized by monoclonal antibodies produced by chronic lymphocytic leukemia B cells. Blood (2009) 1.89